Natural Capsules Limited has informed the Exchange regarding Allotment of 45000 Shares.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited's Board approved the allotment of 45,000 equity shares (face value Rs. 10) to an ex-employee under ESOP 2025, raising Rs. 4.50 lakhs and increasing paid-up capital from Rs. 10.34 crore to Rs. 10.39 crore. The Board also approved unaudited Q3FY26 (quarter ended Dec 31, 2025) standalone and consolidated results. Standalone revenue from operations fell sharply to Rs. 34.15 crore (vs Rs. 43.41 crore in Q3FY25), a ~21% decline, with net profit dropping to Rs. 36.23 lakhs (vs Rs. 170.32 lakhs). On a 9-month basis, standalone PAT grew ~39% to Rs. 5.70 crore. Consolidated Q3 net profit was marginal at Rs. 11.71 lakhs, with the API segment reporting a loss of Rs. 6.40 crore for the quarter due to the subsidiary Natural Biogenex still ramping up post-commencement of commercial operations. One manufacturing unit was temporarily shut down from Dec 26 due to regulatory issues and resumed operations on Jan 30, 2026. The Board also approved a Postal Ballot notice to enhance limits under Section 186 of the Companies Act. Auditor P. Chandrasekar LLP issued an unmodified limited review conclusion.
The sharp Q3 revenue decline and profit drop on a standalone basis are negative signals for the stock, partly explained by the unit shutdown. However, 9-month PAT growth and the ESOP-driven minor dilution (0.04% increase in share count) are relatively neutral. Watch for sustained API segment losses and the impact of the resolved regulatory shutdown on Q4 performance.